Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Current Liabilities (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Total Current Liabilities data on record, last reported at $21.7 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 43.2% year-over-year to $21.7 million; the TTM value through Dec 2025 reached $21.7 million, down 43.2%, while the annual FY2025 figure was $21.7 million, 43.2% down from the prior year.
  • Total Current Liabilities reached $21.7 million in Q4 2025 per TNGX's latest filing, up from $18.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $55.5 million in Q4 2022 and bottomed at $301964.0 in Q1 2021.
  • Average Total Current Liabilities over 5 years is $37.5 million, with a median of $41.3 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 36393.7% in 2021, then plummeted 50.92% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $40.7 million in 2021, then soared by 36.51% to $55.5 million in 2022, then decreased by 17.3% to $45.9 million in 2023, then decreased by 16.91% to $38.2 million in 2024, then tumbled by 43.2% to $21.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $21.7 million in Q4 2025, $18.4 million in Q3 2025, and $40.0 million in Q2 2025.